These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Use of passive immunotherapy in the treatment of experimental Pseudomonas aeruginosa infections in burns. Neely AN; Holder IA Antibiot Chemother (1971); 1987; 39():26-40. PubMed ID: 3118788 [No Abstract] [Full Text] [Related]
45. Active and passive immunity against Pseudomonas aeruginosa with a ribosomal vaccine and antiserum in C3H/HeJ mice. Lieberman MM; Ayala E J Immunol; 1983 Jul; 131(1):1-3. PubMed ID: 6408166 [No Abstract] [Full Text] [Related]
46. [Infection and host responses. (6) Evaluation of Pseudomonas vaccine therapy in refractory infection of the respiratory and transit areas]. Tanimoto H; Tachibana A Nihon Naika Gakkai Zasshi; 1982 Oct; 71(10):1384-8. PubMed ID: 6820039 [No Abstract] [Full Text] [Related]
47. [Investigations on the immunogenicity of Pseudomonas seruginosa strains of different serological O-groups]. Meitert E; Meitert T Zentralbl Bakteriol Orig; 1968; 208(4):515-21. PubMed ID: 5000090 [No Abstract] [Full Text] [Related]
48. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: immunization using divalent flagella preparations. Holder IA; Naglich JG J Trauma; 1986 Feb; 26(2):118-22. PubMed ID: 2418208 [TBL] [Abstract][Full Text] [Related]
49. [The protective activity of 2 normal immunoglobulin preparations for intravenous administration in experimental Pseudomonas aeruginosa infection]. Vasilev ChL; Veleva KV; Tekelieva RKh; Pencheva PI Zh Mikrobiol Epidemiol Immunobiol; 1991 Feb; (2):54-6. PubMed ID: 1907793 [TBL] [Abstract][Full Text] [Related]
51. Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model. Bakht Azad S; Nikokar I; Faezi S; Rasooly S; Mahdavi M Microb Pathog; 2018 Oct; 123():426-432. PubMed ID: 30075242 [TBL] [Abstract][Full Text] [Related]
52. [Immunogenic properties and specificity of pseudomonas aeruginosa polyvalent vaccine]. Schiller B; Lysakowska E; Owczarska K Med Dosw Mikrobiol; 1981; 33(2):91-6. PubMed ID: 6170849 [No Abstract] [Full Text] [Related]
53. Protective characteristics of the antigen common to Pseudomonas and Vibrio and significance of bacterial endotoxins in protection against selected bacterial infections. Sourek J Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Jul; 259(4):538-47. PubMed ID: 2413656 [TBL] [Abstract][Full Text] [Related]
54. Effects of elastase, protease and common antigen (OEP) from Pseudomonas aeruginosa on protection against burns in mice. Kawaharajo K; Homma JY Jpn J Exp Med; 1977 Dec; 47(6):495-500. PubMed ID: 416253 [TBL] [Abstract][Full Text] [Related]
55. [The serological characteristics of the O antigens of Pseudomonas aeruginosa isolated from patients with a Pseudomonas infection during immunotherapy]. Kholodkova EV; Krylov VM; Badikov VD; Sukhovskaia OA; Bazanova EB; Iushkova NA; Stanislavskiĭ ES Zh Mikrobiol Epidemiol Immunobiol; 1991 Aug; (8):59-61. PubMed ID: 1719718 [TBL] [Abstract][Full Text] [Related]
56. Pseudomonas aeruginosa. Vaccines and immunotherapy. Pennington JE Infect Dis Clin North Am; 1990 Jun; 4(2):259-70. PubMed ID: 2111838 [TBL] [Abstract][Full Text] [Related]
58. Construction of a Protective Vaccine Against Lipopolysaccharide-Heterologous Liu C; Pan X; Xia B; Chen F; Jin Y; Bai F; Priebe G; Cheng Z; Jin S; Wu W Front Immunol; 2018; 9():1737. PubMed ID: 30093906 [No Abstract] [Full Text] [Related]
59. [Recent progress of Pseudomonas aeruginosa infections; pathological mechanisms of new toxic metabolites]. Homma JY Nihon Rinsho; 1991 Oct; 49(10):2201-6. PubMed ID: 1749074 [No Abstract] [Full Text] [Related]
60. Clinical use of monovalent vaccines in the treatment of Pseudomonas aeruginosa infection. De Fajardo CL; Delfino AH; Laborde HF Prog Immunobiol Stand; 1971; 5():425-7. PubMed ID: 4633970 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]